Scott Weston

Scott builds and manages patent portfolios for deeptech and medtech companies, often starting at formation with a single patent application or university license and continuing through financing, licensing and, when necessary, enforcement. He also advises the investors and acquirers who evaluate those portfolios. His clients include battery, electric grid, advanced materials, separations and medical device companies.

Scott is a chemical engineer by training. Before practicing law, he spent six years as a project engineer at CMS Energy developing energy infrastructure projects around the globe, including high-pressure natural gas pipelines, processing plants, gas and liquid storage facilities, and independent power plants. That background shapes his practice: he learns each client’s technology and market in depth, builds portfolios around the products and competitive positions that matter commercially, and prioritizes patent spending with the tradeoffs clearly explained as companies grow.

Chambers USA has ranked Scott for Intellectual Property in Massachusetts since 2024. Clients tell Chambers that “Scott offers excellent, actionable advice,” and they credit him with deep knowledge of the technologies he protects; practical, business-oriented guidance; responsiveness; and a clear, efficient hand on complex matters. He also works closely with Cooley’s corporate, M&A, cpital markets, licensing, litigation, regulatory and privacy teams to provide coordinated advice across a company’s lifecycle.

Building portfolios from formation

Many of Scott’s longest client relationships began before the client had a single issued patent. For example, Scott represented 24M Technologies from the time it held only a small foundational portfolio licensed from MIT, building it into a portfolio of hundreds of issued patents worldwide covering electrode compositions and manufacturing, cell architecture, electrolytes, battery safety and packaging, controls, and recycling. He guided that portfolio through numerous financing diligence processes and supported its technology licensing program, identifying the patent assets to be licensed and supporting 24M in responding to diligence by prospective licensees.

He has represented Magnolia Medical Technologies since it had one pending patent application. Its portfolio, covering blood culture collection and contamination-prevention technology, now includes hundreds of issued patents worldwide and has been tested in court. Scott drafted and prosecuted the patents Magnolia asserted against a competitor in Magnolia Medical Technologies, Inc. v. Kurin, Inc., No. 1:24-cv-01124 (D. Del.), where a jury found three of those patents infringed. The asserted patents also withstood a reexamination challenge, emerging with hundreds of claims.

Scott has also represented VEIR, a developer of superconductor-based electric transmission and distribution technology, since its formation, and Via Separations, a developer of membrane-based industrial separations technology, since its founders had just completed graduate school at MIT.

Investor and transaction diligence

Scott has conducted more than 100 patent and IP diligence reviews for venture capital firms, growth investors and strategic acquirers, in transactions ranging from early-stage financings to multibillion-dollar acquisitions. On the investor side, he has performed diligence for Wellington Management, General Catalyst, Khosla Ventures, Forbion, Novo Holdings, Cerberus Capital Management, Northpond Ventures and The Engine Ventures. Strategic clients have included The Clorox Company, in connection with its acquisition of GOJO Industries, maker of Purell, as well as Volcano Corporation and HeartWare, each across multiple investments and acquisitions. His diligence focuses on ownership and chain of title, portfolio quality, commercial relevance, freedom to operate and how identified risks should bear on valuation and deal structure. On the company side, Scott prepares clients for investor and acquirer diligence and manages the process through closing.

From diligence to long-term counsel

Investor diligence often develops into long-term portfolio work. In one example, diligence for an investor led Scott to take over the portfolio of an early-stage advanced materials company with only three pending applications; he subsequently helped build it into a substantial global portfolio. In another, after taking over a medical technology portfolio, Scott rationalized maintenance spending in non-core international jurisdictions and redirected those resources toward protection for later-generation technology. He has also taken over prosecution for Apple Tree Life Sciences portfolio companies following multiple diligence engagements for the firm, and he currently represents several Rhapsody Venture Partners portfolio companies.

Company clients also refer Scott to other emerging companies. VEIR introduced him to TS Conductor, where he expanded a portfolio concentrated in a single patent family into a broad, multi-family portfolio covering its advanced conductor technology.

Ecosystem

Scott is a frequent speaker for startup cohorts through VentureWell, mHUB, Chain Reaction Innovations and HBS Foundry Catalyst on intellectual property issues, with a focus on strategic patent considerations for early-stage companies.